Hutchin Hill Capital’s Pacira BioSciences PCRX Stock Holding History

Hutchin Hill Capital’s Portfolio PCRX Stock Details PCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q2	–	Sell	-7,000	Closed	-$371K	–	677
2016 Q1	$371K	Buy	+7,000	New	+$409K	0.01%	548
2015 Q1	–	Sell	-9,300	Closed	-$825K	–	763
2014 Q4	$825K	Buy	+9,300	New	+$880K	0.03%	360
2014 Q3	–	Sell	-3,033	Closed	-$279K	–	689
2014 Q2	$279K	Buy	+3,033	New	+$231K	0.01%	538

Other funds holding PCRX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

GGHC

Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

DCM

Daruma Capital Management New York $879M AUM 2.11% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Hutchin Hill Capital's PCRX Position: Q2 2016 in Review

Hutchin Hill Capital sold out of Pacira BioSciences (PCRX) in Q2 2016, closing a stake of 7,000 shares — an estimated $371K sold.

Hutchin Hill Capital first reported a position in PCRX in Q2 2014 and held it in 3 quarters. The position peaked at $825K in Q4 2014. 183 funds tracked by Wall St. Rank hold PCRX as of Q2 2016.

Hutchin Hill Capital reported no remaining Pacira BioSciences position as of Q2 2016 after selling out during the quarter.
Hutchin Hill Capital sold 7,000 Pacira BioSciences shares in Q2 2016, an estimated $371K.
Hutchin Hill Capital first reported a position in Pacira BioSciences in Q2 2014 and held it in 3 quarters.
Hutchin Hill Capital's Pacira BioSciences position peaked at $825K in Q4 2014.
183 funds tracked by Wall St. Rank held Pacira BioSciences as of Q2 2016.

Based on Hutchin Hill Capital's 13F filing for Q2 2016, filed 15 Aug 2016.